← All trials
NCT02621164
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2014
- Primary completion
- Feb 1, 2015
- Completion date
- Jun 1, 2015
- First posted
- —
- Last posted
- —
- Enrollment
- 454
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- SK ChemicalsLead sponsor
- Cha Medical UniversityOverall official - principal investigator
- Eulji UniversityOverall official - principal investigator
- Hallym UniversityOverall official - principal investigator
- Korea Institute of Radiological & Medical Sciences (KIRAMS)Overall official - principal investigator
- Korea UniversityStudy chair
- University of UlsanOverall official - principal investigator
- Chonbuk National UniversityOverall official - principal investigator
- Yonsei UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.